Постишемическое невосстановление кровотока: механизмы и терапевтические мишени

Феномен постишемического невосстановления кровотока заключается в отсутствии полноценной перфузии миокарда на уровне микроциркуляторного русла после устранения причины, вызвавшей окклюзию коронарной артерии. Выделяют два основных механизма возникновения феномена невосстановления кровотока, возникающих у пациентов с инфарктом миокарда после первичной чрескожной ангиопластики: проявления ишемического-реперфузионного повреждения микроциркуляторного русла миокарда и эмболизация дистального артериального русла фрагментами тромба и атеросклеротической бляшки. В обзоре описаны факторы, которые способствуют появлению феномена постишемического невосстановления кровотока, механизмы его появления, принципы диагностики и терапевтические мишени.

феномен невосстановления кровотока, инфаркт миокарда, ишемически-реперфузионное повреждение, микроваскулярная обструкция, чрескожное коронарное вмешательство, посткондиционирование, кардиопротекция, no-reflow phenomenon, myocardial infarction, ischemia-reperfusion injury, microvascular obstruction, percutaneous coronary intervention, postconditioning, cardioprotection

1. Кухарчик Г. А., Павлова А. М., Митрофанов Н. А. Возможности магнитно-резонансной томографии сердца при инфаркте миокарда // Вестн. Санкт-Петербург. ун-та: Медицина. - 2012. - T. 11. - № 2. - С. 73-81 [Kukharchik GA, Pavlova AM, Mitrofanov NA. Potentials of Cardiovascular Magnetic Resonance Imaging in Myocardial Infarction. Vestnik Sankt-Peterburgskogo universiteta. Meditsina. 2012;11(2):73-81. (In Russ).]

2. Сидоренко Г. И., Островский Ю. П. Феномен «невозобновления кровотока» (no-reflow) и его клиническое значение // Кардиология. - 2002. - № 5. - C. 74-80 [Sidorenko GI, Ostrovskiy YUP. Fenomen «nevozobnovleniya krovotoka» (no-reflow) i yego klinicheskoye znacheniye. Kardiologiya. 2002;5:74-80. (In Russ).]

3. Alfayoumi F, Srinivasan V, Geller M, et al. The no-reflow phenomenon: epidemiology, pathophysiology, and therapeutic approach. Rev Cardiovasc Med. 2005;6(2):72-83.

4. Bahrmann P, Werner GS, Heusch G, et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation. 2007;115(5):600-608. doi: 10.1161/CIRCULATIONAHA.106.660779

5. Bertuglia S, Giusti A. Microvascular oxygenation, oxidative stress, NO suppression and superoxide dismutase during postischemic reperfusion. Am J Physiol Heart Circ Physiol. 2003;285(3):H1064-H1071. doi: 10.1007/0-387-26206-7 4.

6. Burzotta F, Testa L, Giannico F, et al. Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials. Int. J. Cardiol. 2008;123(3):313-321. doi: 10.1016/j.ijcard.2006.12.018.

7. Burzotta F, Trani C, Romagnoli E et al. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J Am Coll Cardiol. 2005;46:371-376. doi: 10.1016/j.jacc.2005.04.057.

8. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol. 2006;48:2178-2185. doi: 10.1016/j.jacc.2005.12.085.

9. Chen WH, Lee PY, Ng W. et al. Safety and feasibility of the use of a distal filter protection device in percutaneous revascularization of small coronary arteries. Catheter Cardiovasc Interv. 2004;61(3):360-363. doi: 10.1002/ccd.10791.

10. Collet JP, Montalescot G. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes. Diabetes Vasc Dis Res. 2005;2:136-143. doi: 10.3132/dvdr.2005.021.

11. Czarnowska E, Karwatowska-Prokopczuk E. Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart. Involvement of oxygen free radicals. Basic Res Cardiol. 1995;90:357-364. doi: 10.1007/BF00788496.

12. Desch S, Stiermaier T, de Waha S, et al. Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset. JACC Cardiovasc Interv. 2016;9(2):113-22. doi: 10.1016/j.jcin.2015.09.010.

13. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98(7):699-710. doi: 10.1161/01. CIR.98.7.699.

14. Gao XM, Wu QZ, Kiriazis H, et al. Microvascular leakage in acute myocardial infarction: characterization by histology, biochemistry, and magnetic resonance imaging. Am J Physiol Heart Circ Physiol. 2017;312(5):H1068-H1075. doi: 10.1152/ajpheart.00073.2017.

15. Gilles S, Zahler S, Welsch U, et al. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc Res. 2003;60:608-616. doi: 10.1016f.cardiores.2003.08.016.

16. Glazier JJ. Attenuation of reperfusion microvascular ischemia by aqueous oxygen: experimental and clinical observations. Am Heart J. 2005;149(4):580-584. doi: 10.1016/j.ahj.2004.12.009.

17. Golino P, Maroko PR, Carew TE. The effect of acute hypercholesterolemia on myocardial infarct size and the noreflow phenomenon during coronary occlusion-reperfusion. Circulation. 1987;75:292-298. doi: 10.1161/01.CIR.75.1.292.

18. Golino P, Ragni M, Cirillo P et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med. 1996;2(1):35-40. doi: 10.1038/nm0196-35.

19. Hale SL, Dae M, Kloner RA. Hypothermia during reperfusion limits "no-reflow" injury in a rabbit model of acute myocardial infarction. Cardiovasc Res. 2003;59(3):715-722. doi: 10.1016/S0008-6363(03)00456-5.

20. Hale SL, Kloner RA. The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit. J Cardiovas Pharmacol Therap. 2008;13(3):226-232. doi: 10.1177/1074248408320278.

21. Han JY, Horie Y, Fan JY, et al. Potential of 3,4-dihydroxy-phenyl lactic acid for ameliorating ischemia-reperfusion-induced microvascular disturbance in rat mesentery. Am J Physiol Gastrointest Liver Physiol. 2009;296(1):G36-44. doi: 10.1152/ajpgi.90284.2008.

22. Harris NR, Rumbaut RE. Age-related responses of the microcirculation to ischemia-reperfusion and inflammation. Pathophysiology. 2001;1:1-10. doi: 10.1016/s0928-4680(01)00064-5.

23. Hayat SA, Senior R. Myocardial contrast echocardiography in ST elevation myocardial infarction: ready for prime time? Eur Heart J. 2008;29:299-314. doi: 10.1093/eurheartj/ehm621.

24. Hervas A, de Dios E, Forteza MJ, Mwana G, Nuсez J et al. Intracoronary Infusion of Thioflavin-S to Study Microvascular Obstruction in a Model of Myocardial Infarction. Rev Esp Cardiol (Engl Ed). 2015;68(11):928-34. doi: 10.1016/j. rec.2015.04.016.

25. Heusch G. The Coronary Circulation as a Target of Cardioprotection. Circ Res. 2016;118(10):1643-58. doi: 10.1161/CIRCRESAHA.116.308640.

26. Higginson LA, White F, Heggtveit HA, et al. Determinants of myocardial hemorrhage after coronary reperfusion in the anesthetized dog. Circulation. 1982;65:62-69. doi: 10.1161/01.CIR.65.1.62.

27. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1-7. doi: 10.1016/S0735-1097(02)02626-8.

28. Iwakura K, Ito H, Kawano S et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol. 2001;38:472-477. doi: 10.1016/S0735-1097(01)01405-X.

29. Kereiakes DJ, Turco MA, Breall J et al. A novel filter-based distal embolic protection device for percutaneous in tervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. JACC Cardiovasc Interv. 2008;1(3):248-257. doi: 10.1016/j.jcin.2008.03.009.

30. Kleinbongard P, Bose D, Baars T et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res. 2011;108(3):344-352. doi: 10.1161/CIRCRESAHA.110.235713.

31. Kloner R. A. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharm Ther. 2011;16(3-4):244-250. doi: 10.1177/1074248411405990.

32. Kloner R. A. No-reflow: Basic science to clinical phenomenon. Basic Res Cardiol. 2006;101(9):357-358. doi: 10.1136/heart.87.2.162.

33. Kloner RA, Ganote CE, Jennings RB. The «no-reflow» phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508. doi: 10.1172/JCI107898.

34. Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation. 1980;62:945-952. doi: 10.1161/01.CIR.62.5.945.

35. Limbruno U, De Carlo M, Pistolesi S, et al. Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J. 2005;150:102-108. doi: 10.1016/j.ahj.2005.01.016.

36. McLaughlin MG, Stone GW, Aymong E, et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol. 2004;44:1215-1223. doi: 10.1016/j.jacc.2004.06.053.

37. Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med. 2007;357:1631-1638. doi: 10.1056/NEJMra065985.

38. Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55(21):2383-9. doi: 10.1016/j.jacc.2009.12.054.

39. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54(4):281-292. doi: 10.1016/j.jacc.2009.03.054.

40. Niccoli G, Giubilato S, Russo E et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J. 2008;29:1843-1850. doi: 10.1093/eurheartj/ehn325.

41. Niccoli G, Lanza G A, Shaw S et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur. Heart J. 2006;27:1793-1798. doi: 10.1093/eurheartj/ehl119.

42. Niccoli G, Marino M, Spaziani C et al. Prevention and treatment of no-reflow. Acute Card Care. 2010;12(3):81-91. doi: 10.3109/17482941.2010.498919.

43. Pochkaeva EI, Sonin DL, Larionov AA et al. Fluorescent indocyanine green imaging enables in vivo and ex vivo quantification of myocardial infarct size. [abstract] European Heart Journal. 2016;37(1):50.

44. Porto I, Selvanayagam JB, Van Gaal WJ et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation. 2006;114(7):662-669. doi: 10.1161/CIRCULATIONAHA.105.593210.

45. Przyklenk K, Kloner RA. Reperfusion injury by oxygen-free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. Circ Res. 1989;64(1):86-96. doi: 10.1161/01.RES.641.86.

46. Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no-reflow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol. 2002;283(3):H1099-H1107. doi: 10.1152/ajpheart.00270.2002.

47. Reffelmann T, Kloner RA. The «no-reflow» phenomenon: basic science and clinical correlates. Heart. 2002;87(2):162- 168. doi: 10.1136/heart.87.2162.

48. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006;101:359-372. doi: 10.1007/s00395-006-0615-2.

49. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008;72:950- 957. doi: 10.1002/ccd.21715.

50. Rezkalla SH, Stankowski RV, Hanna J et al. Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC Cardiovasc Interv. 2017;10(3):215-223. doi: 10.1016/j.jcin.2016.11.059.

51. Bolognese Sorajja P, Gersh BJ, Costantini C et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J. 2005;26:667-674. doi: 10.1093/eurheartj/ehi167.

52. Stone GW, Martin JL, de Boer MJ et al. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv, 2009;2(5):366-375. doi: 10.1161/CIRCINTERVENTIONS.108.840066.

53. Stone GW, Maehara A, Witzenbichler B et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. INFUSE-AMI Investigators. JAMA. 2012;307(17):1817-26. doi: 10.1001/jama.2012.421.

54. Svilaas T, Vlaar PJ, van der Horst IC et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008,358:557-567. doi: 10.1056/NEJMoa0706416.

55. Takahashi T, Hiasa Y, Ohara Y et al. Relation between neutrophil counts on admission, microvascular injury, and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty. Am J Cardiol. 2007,100:35-40. doi: 10.1016/j.amjcard.2007.02.049.

56. The TIMI Study Group. The Thrombolysis In Myocardial Infarction [TIMI] trial. Phase I findings. N Engl J Med. 1985,312:932-936. doi: 10.1056/NEJM198504043121437.

57. Thiele H, Schindler K, Friedenberger J et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primarypercutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642.

58. Thiele H, de Waha S, Zeymer U et al. Effect of aspiration thrombectomy on microvascular obstruction in NSTEMI patients: the TATORT-NSTEMI trial. J Am Coll Cardiol. 2014;64(11):1117-24. doi: 10.1016/j.jacc.2014.05.064.

59. Turschner O, D'Hooge J, Dommke C et al. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur Heart J. 2004; 25:794-803. doi: 10.1016/j.ehj.2004.01.006.

60. Valent P, Sillaber C, Baghestanian M et al. What have mast cells to do with edema formation, the consecutive repair and fibrinolysis? Int Arch Allergy Immunol. 1998;115(1):2-8. doi: 10.1159/000023823.

61. Van Gaal WJ, Banning AP. Percutaneous coronary intervention and the no-reflow phenomenon. Expert Rev Cardiovasc Ther. 2007;5(4):715-731. doi: 10.1586/14779072.5.4.715.

62. Van't Hof AW, Liem A, Suryapranata H et al. Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation. 1998,97:2302-2306. doi: 10.1161/01.CIR.97.23.2302.

63. Van Kranenburg M, Magro M, Thiele H et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging. 2014;7(9):930-9. doi: 10.1016/j.jcmg.2014.05.010.

64. Vignali L, Talanas G, Saia F et al. Genetic association between the 1976T_C polymorphism in the adenosineA2 receptor and angiographic no-reflow phenomenon. [abstract] Il Giornale italiano di Cardiologia Invasiva, 2007;3(1):109.

65. Vlaar PJ, Svilaas T, van der Horst IC et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915-1920. doi: 10.1016/S0140-6736(08)60833-8.

66. Wong DT, Leung MC, Richardson JD et al. Cardiac magnetic resonance derived late microvascular obstruction assessment post ST-segment elevation myocardial infarction is the best predictor of left ventricular function: a comparison of angiographic and cardiac magnetic resonance derived measurements. Int J Cardiovasc Imaging. 2012;28(8):1971-81. doi: 10.1007/s10554-012-0021-9.

67. Wu KC. CMR of microvascular obstruction and hemorrhage in myocardial infarction. J Cardiovasc Magn Reson. 2012;14:68. doi: 10.1186/1532-429X-14-68.

68. Yip HK, Chen MC, Chang HW et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002;122:1322-1332. doi: 10.1378/chest.122.4J322.

69. Zaman AK, French CJ, Spees JL et al. Vascular rhexis in mice subjected to non-sustained myocardial ischemia and its therapeutic implications. Exp Biol Med (Maywood). 2011;236(5):598-603. doi: 10.1258/ebm.2011.011026.